Search results for "Plasmin"

showing 10 items of 176 documents

p53 and p53-related mediators PAI-1 and IGFBP-3 are downregulated in peripheral blood mononuclear cells of HIV-patients exposed to non-nucleoside rev…

2019

The improved effectiveness and safety of the combined antiretroviral therapy (cART) has largely diminished mortality and AIDS-defining morbidity of HIV-patients. Nevertheless, chronic age-related diseases in these individuals are more common and their underlying pathogenic mechanisms of these actions seem to involve accelerated aging and enhanced inflammation. The present study explores markers of these processes in a heterogenous Spanish HIV cohort using peripheral blood samples of HIV-patients and matched uninfected controls. We isolated periheral blood mononuclear cells (PBMCs) and i) compared the expression of a panel of 14 genes related to inflammation and senescence in PBMCs of HIV-pa…

0301 basic medicineSenescenceAdultMaleAnti-HIV Agents030106 microbiologyDown-RegulationInflammationHIV InfectionsCCL2Peripheral blood mononuclear cell03 medical and health sciencesVirologyAntiretroviral Therapy Highly ActivePlasminogen Activator Inhibitor 1medicineCXCL10HumansCellular SenescencePharmacologyInflammationbusiness.industryInterleukin-6Interleukin-18virus diseasesMiddle AgedCCL20Chemokine CXCL10030104 developmental biologyInsulin-Like Growth Factor Binding Protein 3ImmunologyLeukocytes MononuclearReverse Transcriptase InhibitorsInterleukin 18Tumor necrosis factor alphaFemalemedicine.symptomTumor Suppressor Protein p53businessAntiviral research
researchProduct

Long-term vitamin D treatment decreases human uterine leiomyoma size in a xenograft animal model

2019

Objective To study the effects of short- and long-term vitamin D treatment on uterine leiomyomas in vivo through cell proliferation, extracellular matrix (ECM) degradation, and apoptosis. Design Preclinical study of human leiomyoma treatment with vitamin D in an nonhuman animal model. Setting Hospital and university laboratories. Patient(s)/Animal(s) Human leiomyomas were collected from patients and implanted in ovariectomized NOD-SCID mice. Intervention(s) Mice were treated with vitamin D (0.5 μg/kg/d or 1 μg/kg/d) or vehicle for 21 or 60 days. Main Outcome Measure(s) Vitamin D effect in xenograft tissue was assessed by monitoring tumor size (18F-FDG positron-emission tomography/computeriz…

0301 basic medicineVitaminmedicine.medical_specialtyMice SCIDDrug Administration ScheduleMice03 medical and health scienceschemistry.chemical_compound0302 clinical medicineMice Inbred NODPositron Emission Tomography Computed TomographyInternal medicinemedicineVitamin D and neurologyAnimalsHumansVitamin DCell Proliferation030219 obstetrics & reproductive medicineUterine leiomyomaLeiomyomabusiness.industryObstetrics and Gynecologymedicine.diseaseXenograft Model Antitumor AssaysTumor BurdenBlotTreatment Outcome030104 developmental biologyLeiomyomaEndocrinologyReproductive MedicinechemistryApoptosisPlasminogen activator inhibitor-1Ovariectomized ratFemalebusinessFertility and Sterility
researchProduct

Enhancement of Wound Healing in Normal and Diabetic Mice by Topical Application of Amorphous Polyphosphate. Superior Effect of a Host⁻Guest Composite…

2017

The effect of polyphosphate (polyP) microparticles on wound healing was tested both in vitro and in a mice model in vivo. Two approaches were used: pure salts of polyphosphate, fabricated as amorphous microparticles (MPs, consisting of calcium and magnesium salts of polyP, “Ca–polyp-MPs” and “Mg–polyp-MPs”), and host–guest composite particles, prepared from amorphous collagen (host) and polyphosphate (guest), termed “col/polyp-MPs”. Animal experiments with polyP on healing of excisional wounds were performed using both normal mice and diabetic mice. After a healing period of 7 days “Ca–polyp-MP” significantly improved re-epithelialization in normal mice from 31% (control) to 72% (polyP micr…

0301 basic medicinecollagenMaterials sciencePolymers and PlasticsPAI-1chemistry.chemical_elementpolyphosphate; microparticles; delayed wound healing; collagen; PAI-1; re-epithelialization; diabetic mice02 engineering and technologymacromolecular substancesCalciumdiabetic miceArticlelcsh:QD241-44103 medical and health scienceschemistry.chemical_compoundlcsh:Organic chemistryIn vivootorhinolaryngologic diseasesre-epithelializationneoplasmsmicroparticlesPolyphosphateDiabetic mousepolyphosphateGeneral Chemistry021001 nanoscience & nanotechnologyMolecular biologyIn vitrodigestive system diseases3. Good healthAmorphous solid030104 developmental biologysurgical procedures operativechemistry0210 nano-technologyWound healingPlasminogen activatordelayed wound healingPolymers
researchProduct

Micro-RNA profile and proteins in peritoneal fluid from women with endometriosis: their relationship with sterility.

2018

Objective: To define the microRNA (miRNA) profile and its relationship with cytokines content in peritoneal fluid (PF) from endometriosis patients. Design: Case-control study. Setting: University hospital, research institute. Patient(s): One hundred twenty-six women with endometriosis (EPF) and 45 control women (CPF). Main Outcomes Measure(s): MiRNA arrays were prepared from six EPF and six CPF. Quantitative reverse transcription-polymerase chain reaction validation of nine selected miRNAs (miR-29c-3p, -106b-3p, -130a-3p, -150-5p, -185-5p, -195-5p, -451a, -486-5p, and -1343-5p) was performed. Vascular endothelial growth factor-A (VEGF-A), thrombospondin-1 (TSP-1), urokinase plasminogen acti…

0301 basic medicineendometriosisAdultProteomicsMMP3AngiogenesisEndometriosisEndometriosisEnzyme-Linked Immunosorbent AssayAndrology03 medical and health sciences0302 clinical medicinePregnancymedicineAscitic FluidHumansAngiogenic ProteinsMacrophage inflammatory proteinOligonucleotide Array Sequence Analysis030219 obstetrics & reproductive medicinemicroRNAbusiness.industryPeritoneal fluidGene Expression ProfilingObstetrics and GynecologyInterleukinProteinsMiddle Agedmedicine.diseaseFold changeMicroRNAs030104 developmental biologyperitoneal fluidFertilityReproductive MedicineinflammationCase-Control StudiesCytokinesFemaleAngiogenesisInflammation MediatorsbusinessTranscriptomePlasminogen activatorInfertility FemaleFertility and sterility
researchProduct

Measurement of Bradykinin Formation and Degradation in Blood Plasma: Relevance for Acquired Angioedema Associated With Angiotensin Converting Enzyme …

2020

Bradykinin (BK)-mediated angioedema (AE) states are rare acquired or hereditary conditions involving localized edema of the subcutaneous and submucosal tissues. Citrated plasma from healthy volunteers or patients with hereditary angioedema (HAE) with normal level of C1-inhibitor (C1-INH) was used to investigate pathways of BK formation and breakdown relevant to AE physiopathology. The half-life of BK (100 nM) added to normal plasma was 34 s, a value that was increased ~12-fold when the angiotensin converting enzyme (ACE) inhibitor enalaprilat (130 nM) was added (enzyme immunoassay measurements). The BK half-life was similarly increased ~5-fold following 2 daily oral doses of enalapril malea…

0301 basic medicinemedicine.medical_specialtykallikreinsPlasminBradykininTissue plasminogen activator03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicinemedicineB2 receptorsOriginal ResearchplasminFactor XIIlcsh:R5-920tissue plasminogen activatorAngioedemabiologyhereditary angioedema with normal C1 inhibitor levelAngiotensin-converting enzymeGeneral MedicineKallikreinmedicine.disease030104 developmental biologyEndocrinology030228 respiratory systemchemistryHereditary angioedemabiology.proteinMedicinemedicine.symptombradykininlcsh:Medicine (General)medicine.drugFrontiers in Medicine
researchProduct

Deficiency of plasminogen activator inhibitor 2 in plasma of patients with hereditary angioedema with normal C1 inhibitor levels

2016

Background Hereditary angioedema with normal C1 inhibitor levels (HAE-N) is associated with a Factor XII mutation in 30% of subjects; however, the role of this mutation in the pathogenesis of angioedema is unclear. Objective We sought evidence of abnormalities in the pathways of bradykinin formation and bradykinin degradation in the plasma of patients with HAE-N both with and without the mutation. Methods Bradykinin was added to plasma, and its rate of degradation was measured by using ELISA. Plasma autoactivation was assessed by using a chromogenic assay of kallikrein formation. Plasminogen activator inhibitors (PAIs) 1 and 2 were also measured by means of ELISA. Results PAI-1 levels varie…

0301 basic medicinemedicine.medical_specialtymedicine.medical_treatmentImmunologyBradykinin030204 cardiovascular system & hematologyArticleC1-inhibitor03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineFibrinolysismedicineImmunology and AllergyFactor XIIAngioedemabiologybusiness.industryKallikreinmedicine.disease030104 developmental biologyEndocrinologychemistryPlasminogen activator inhibitor-1Hereditary angioedemabiology.proteinmedicine.symptombusinessJournal of Allergy and Clinical Immunology
researchProduct

Wilson’s Disease: Facing the Challenge of Diagnosing a Rare Disease

2021

Wilson disease (WD) is a rare disorder caused by mutations in ATP7B, which leads to the defective biliary excretion of copper. The subsequent gradual accumulation of copper in different organs produces an extremely variable clinical picture, which comprises hepatic, neurological psychiatric, ophthalmological, and other disturbances. WD has a specific treatment, so that early diagnosis is crucial to avoid disease progression and its devastating consequences. The clinical diagnosis is based on the Leipzig score, which considers clinical, histological, biochemical, and genetic data. However, even patients with an initial WD diagnosis based on a high Leipzig score may harbor other conditions th…

<i>ATP7B</i> geneQH301-705.5Wilson’s diseaseMedicine (miscellaneous)ReviewWilson-likeDiseaseBioinformaticsGeneral Biochemistry Genetics and Molecular BiologymedicineBiology (General)24 h urinebiologybusiness.industryDisease progressionbiomarkersGenetic dataATP7B genegenetic modifiersmedicine.diseaseWilson's diseaseClinical diagnosisbiology.proteinLeipzig scaleCeruloplasminbusinessRare diseaseBiomedicines
researchProduct

Coronavirus Disease 2019–Associated Coagulopathy

2021

Patients with the severe form of coronavirus disease 2019 (COVID-19) have been frequently found to suffer from both arterial and venous thrombotic events due to the perpetuation of a hypercoagulable state. This phenomenon, termed COVID-19-associated coagulopathy (CC), is now considered a major component of the pathophysiology of this novel infectious disease, leading to widespread thrombosis. While at first, the vascular insults may be limited to the pulmonary microvasculature, as the disease progresses, systemic involvement occurs, culminating in distant organ thrombosis and multi-organ dysfunction syndrome. In this review article, we discuss recent insights into the pathophysiologic mecha…

ARDSPAI-1 Plasminogen Activator Inhibitor 1VTE venous thromboembolismDiseaseReview030204 cardiovascular system & hematologyCoronavirus Disease 20190302 clinical medicineCoagulopathy030212 general & internal medicineDIC disseminated intravascular coagulationDisseminated intravascular coagulationCOVID-19 Coronavirus disease 2019DVT deep vein thrombosisGeneral MedicineBlood Coagulation DisordersThrombosisICU intensive care unitTMA thrombotic microangiopathyDisease ProgressionCoronavirus Disease 2019 COVID-19 CoagulopathyVWF von Willebrand factormedicine.medical_specialtyThrombotic microangiopathyACE2 angiotensin-converting enzyme 2SARS-CoV-2 severe acute respiratory syndrome coronavirus 203 medical and health sciencesmedicineCoagulopathyHumansIntensive care medicineLY30 lysis at 30 minutesARDS acute respiratory distress syndromeHemostasisNO nitric oxideCoagulationbusiness.industrySARS-CoV-2COVID-19Thrombosismedicine.diseasetPA tissue plasminogen activatorReview articleIL interleukinCoronavirusVascular DisorderPE pulmonary embolismTF tissue factorbusinessCC COVID-associated coagulopathyMayo Clinic Proceedings
researchProduct

Systematic Analysis of Combined Thrombolysis Using Ultrasound and Different Fibrinolytic Drugs in an in Vitro Clot Model of Intracerebral Hemorrhage.

2021

Adequate removal of blood clots by minimally invasive surgery seems to correlate with a better clinical outcome in patients with intracerebral hemorrhages (ICHs). Moreover, neurotoxic effects of recombinant tissue plasminogen activator have been reported. The aim of this study was to improve fibrinolysis using an intra-clot ultrasound application with tenecteplase and urokinase in our established ICH clot model. One hundred thirty clots were produced from 25 or 50 mL of human blood, incubated for different periods and equipped with drainage, through which an ultrasound catheter was placed in 65 treatment clots for 1 h, randomly allocated into three groups: administration of ultrasound, admi…

Acoustics and UltrasonicsMechanical Thrombolysismedicine.medical_treatmentUltrasonic TherapyBiophysicsTenecteplase030204 cardiovascular system & hematologyIn Vitro Techniques03 medical and health sciences0302 clinical medicineFibrinolytic AgentsFibrinolysismedicineHumansRadiology Nuclear Medicine and imagingThrombolytic TherapyCerebral HemorrhageIntracerebral hemorrhageUrokinaseRadiological and Ultrasound Technologybusiness.industryUltrasoundThrombosisThrombolysismedicine.diseaseCombined Modality TherapyUrokinase-Type Plasminogen ActivatorIn vitroCatheterAnesthesiaTenecteplasebusiness030217 neurology & neurosurgerymedicine.drugUltrasound in medicinebiology
researchProduct

Aceruloplasminaemia: a family with a novel mutation and long-term therapy with deferasirox.

2014

Ceruloplasmin is a member of the multicopper oxidase family that plays a major role in the transport of iron in the body. Aceruloplasminaemia (ACP) is a rare disease and is clinically identified by iron overload in liver, pancreas, brain, and other organs, and by microcytic anaemia. So far, the iron chelator deferasirox was given for therapy only up to 6 months due to side effects. Here, we describe a novel mutation leading to ACP and report for the first time a long-term therapy, that is, 2 years with deferasirox. ACP was diagnosed in 3 siblings using clinical and biochemical characteristics, HFE and ceruloplasmin mutational analysis, liver biopsy, brain-, liver-, and heart-MRI. For iron d…

AdultBlood GlucoseMalemedicine.medical_specialtyEndocrinology Diabetes and MetabolismIronClinical BiochemistryCarbohydrate metabolismBiochemistryBenzoatesEndocrinologyInsulin resistanceHepcidinInternal medicineGermanyMedicineHumansChelating Agentsbiologymedicine.diagnostic_testbusiness.industryBiochemistry (medical)DeferasiroxCeruloplasminNeurodegenerative DiseasesGeneral MedicineTriazolesmedicine.diseaseIron Metabolism DisordersMagnetic Resonance ImagingPedigreeDeferasiroxEndocrinologymedicine.anatomical_structureTreatment OutcomeLiverLiver biopsyMutationbiology.proteinFemaleChromosomes Human Pair 3businessCeruloplasminPancreasmedicine.drugRare diseaseHormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme
researchProduct